Persistent Inflammation, Stem Cell–Induced Systemic Anti‐Inflammatory Effects, and Need for Repeated Stem Cell Injections: Critical Concepts Influencing Optimal Stem Cell Strategies for Treating Acute Myocardial Infarction and Heart Failure

The therapeutic potential of stem cell treatment for patients with either acute myocardial infarction (AMI) or heart failure (HF) began >15 years ago. Many preclinical studies have been published demonstrating stem cell administration improves myocardial function in animal models of AMI and of HF.

[1]  Mohammad R. Ostovaneh,et al.  Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. , 2020, European heart journal.

[2]  R. Bolli,et al.  Repeated Administrations of Cardiac Progenitor Cells Are Superior to a Single Administration of an Equivalent Cumulative Dose , 2018, Journal of the American Heart Association.

[3]  S. Epstein,et al.  Paracrine-Mediated Systemic Anti-Inflammatory Activity of Intravenously Administered Mesenchymal Stem Cells: A Transformative Strategy for Cardiac Stem Cell Therapeutics , 2017, Circulation research.

[4]  S. Fisher,et al.  Cochrane Corner: stem cell therapy for chronic ischaemic heart disease and congestive heart failure , 2017, Heart.

[5]  M. Dorobanțu,et al.  Fifteen years of bone marrow mononuclear cell therapy in acute myocardial infarction , 2017, World journal of stem cells.

[6]  S. Epstein,et al.  Intravenously Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy , 2017, Circulation research.

[7]  B. Gersh,et al.  Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial , 2016, European heart journal.

[8]  T. Henry,et al.  Consistently Inconsistent-Bone Marrow Mononuclear Stem Cell Therapy Following Acute Myocardial Infarction: A Decade Later. , 2016, Circulation Research.

[9]  R. Bolli,et al.  Repeated Administrations of Cardiac Progenitor Cells Are Markedly More Effective Than a Single Administration: A New Paradigm in Cell Therapy. , 2016, Circulation research.

[10]  Edwin Wu,et al.  Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction. , 2016, Journal of the American College of Cardiology.

[11]  C. Borlongan,et al.  Extracardiac-Lodged Mesenchymal Stromal Cells Propel an Inflammatory Response against Myocardial Infarction via Paracrine Effects , 2016, Cell transplantation.

[12]  Wei Sun,et al.  Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells. , 2015, Journal of the American College of Cardiology.

[13]  R. Bonow,et al.  Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). , 2014, Journal of the American College of Cardiology.

[14]  B. V. Van Tassell,et al.  Targeting interleukin-1 in heart disease. , 2013, Circulation.

[15]  Roberto Bolli,et al.  Cell Therapy for Heart Failure: A Comprehensive Overview of Experimental and Clinical Studies, Current Challenges, and Future Directions , 2013, Circulation research.

[16]  William Wijns,et al.  Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. , 2013, Journal of the American College of Cardiology.

[17]  D. Kastner,et al.  Autoinflammatory Disease Reloaded: A Clinical Perspective , 2010, Cell.

[18]  M. Burnett,et al.  Insights Into the Role of Infection in Atherogenesis and in Plaque Rupture , 2009, Circulation.

[19]  D. Prockop,et al.  Concise Review: Mesenchymal Stem/Multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair—Current Views , 2007, Stem cells.

[20]  S. Epstein,et al.  Mesenchymal Stem Cell Therapy for the Treatment of Heart Failure Caused by Ischemic or Non-ischemic Cardiomyopathy: Immunosuppression and Its Implications. , 2017, Handbook of experimental pharmacology.